Skip to main content
Bal Pharma Ltd. logo

Bal Pharma Ltd. — Investor Relations & Filings

Ticker · BALPHARMA ISIN · INE083D01012 LEI · 254900F3KMK38GUDIW74 BSE.NS Manufacturing
Open in API
Filings indexed 564 across all filing types
Latest filing 2026-05-27 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS BALPHARMA

About Bal Pharma Ltd.

https://www.balpharma.com/

Bal Pharma Ltd. specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations. The organization operates manufacturing facilities compliant with international quality standards, including WHO-GMP certifications. Its product portfolio encompasses a wide range of therapeutic segments, including diabetology, cardiology, gastroenterology, oncology, and pain management. Notable APIs in its catalog include Gliclazide, Ebastine, and Benzydamine. The company maintains an integrated business model, supporting operations from research and development to large-scale production. Bal Pharma serves a global clientele, exporting its products to numerous international markets across multiple continents, while focusing on the delivery of high-quality medicinal products and specialized formulations.

Recent filings

Filing Released Lang Actions
Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recomme
Interim / Quarterly Report Classification · 85% confidence The document comprises the Board meeting outcome that approves and records the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, includes the auditor’s unmodified opinion, full auditor’s report and the detailed financial tables. It goes well beyond a brief earnings summary (ER) and is not a full-form annual report (10-K), but rather a comprehensive financial report for a quarterly and year-end period filed under SEBI LODR. Therefore it best fits the Interim / Quarterly Report category. FY 2026
2026-05-27 English
Corrigendum
Board/Management Information Classification · 88% confidence The document is an addendum to a previously filed notice of a Board of Directors meeting under SEBI Listing Regulations, specifying additional agenda items (fund raising through preferential issue warrants). This pertains to changes in the company’s board meeting agenda (management/board information). It is not a full report, earnings release, or financial statement, but rather a management announcement regarding board meetings. Therefore, it falls under Board/Management Information (MANG).
2026-05-22 English
In addition to the agenda items mentioned in our board meeting notice dated 18.05.2025, the following agenda item will also be considered at the meeting scheduled on 27.05.2026. 1. To ....
Regulatory Filings Classification · 52% confidence The document is an addendum to a Board Meeting notice under SEBI Listing Regulations, providing additional agenda items (fundraising proposal) and not containing substantive financial results, management change, or the actual report itself. It is a miscellaneous regulatory announcement and fits the fallback category. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-22 English
Annual Secretarial Compliance Report for the financial year ended 31.03.2026.
Regulatory Filings Classification · 85% confidence The document is an “Annual Secretarial Compliance Report” submitted under SEBI (LODR) Regulation 24A for the financial year ended 31 March 2026, certified by the practising Company Secretary. It is an officer attestation/compliance certificate and does not contain financial statements or constitute an annual or interim report. Per the certification rule for officer attestations and general regulatory compliance documents, this should be classified as a Regulatory Filing (RNS) rather than as an annual report or audit.
2026-05-22 English
Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve 1. Audited financial results of ....
Regulatory Filings Classification · 82% confidence The document is a formal compliance notice under SEBI (LODR) Regulation 29 to the stock exchanges, informing of the date and agenda of an upcoming Board of Directors meeting. It does not itself present financial results or constitute an actual report, nor does it announce changes in board membership. It is a regulatory filing/announcement of a meeting notice, fitting the general “Regulatory Filings” category (RNS) as a fallback for exchange compliance filings that do not match other specific categories.
2026-05-18 English
Resignation of Director/KMP/SMP
Regulatory Filings
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.